roscovitine

Description: Seliciclib (also known as Roscovitine, CYC202) is a novel, potent, selective and orally bioavailable small-molecule CDK inhibitor with IC50 of 0.65 uM, 0.7 uM and 0.16 uM for Cdc2, CDK2 and CDK5 in cell-free assays. In addition, this agent appears to interfere with CDK-mediated phosphorylation of the carboxy-terminal domain of RNA polymerase II, inhibiting RNA polymerase II-dependent transcription, which may result in the down-regulation of antiapoptotic proteins such as induced myeloid leukemia cell differentiation protein Mcl-1.

References: Eur J Biochem. 1997 Jan 15; 243(1-2):527-36; Cancer Res. 2005 Oct 15; 65(20):9320-7.

Seliciclib, R-Roscovitine; Roscovitin; Roscovitine; CYC202; CYC202; CYC202; CYC 202;

Chemical Name: (R)-2-((6-(benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol

SMILES Code: CC[CH](NC1=NC(NCC2=CC=CC=C2)=C3N=CN(C(C)C)C3=N1)CO

Exact Mass: 354.21681